(Q24197473)

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Low-dose subcutaneous ketamine infusion and morphine tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Ketamine for chronic noncancer pain: concerns regarding toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Subpial vacuolar myelopathy after intrathecal ketamine: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Ketamine for cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Continuous subcutaneous injection of ketamine for cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Ketamine for pain: an update of uses in palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

High-dose ketamine in the management of cancer-related neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

The behavioral pharmacology of NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Successful use of ketamine for central pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

A new definition of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003351.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD003351.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

3619247

3619247

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference